Showing results (1141-1150 of 1,202) with videos related to

Sort By:
Pageof 121
The New England Journal of Medicine|December 25, 2015
Selexipag for the Treatment of Pulmonary Arterial HypertensionOlivier Sitbon, Richard Channick, Kelly M Chin, et al.
The Lancet. Respiratory Medicine|October 18, 2016
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION studyMarius M Hoeper, Vallerie V McLaughlin, Joan Albert Barberá, et al.
Annals of Global Health|September 27, 2021
Call for Emergency Action to Limit Global Temperature Increases, Restore Biodiversity, and Protect Health: Wealthy Nations Must do Much More, Much FasterLukoye Atwoli, Abdullah H Baqui, Thomas Benfield, et al.
Science (New York, N.Y.)|December 8, 2022
Tuberculosis treatment failure associated with evolution of antibiotic resilienceQingyun Liu, Junhao Zhu, Charles L Dulberger, et al.
Circulation. Cardiovascular Quality and Outcomes|May 22, 2019
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare DiseasesAdam Torbicki, Marisa Bacchi, Marion Delcroix, et al.
Nature Genetics|November 7, 2018
Retinoic acid and BMP4 cooperate with p63 to alter chromatin dynamics during surface epithelial commitmentJillian M Pattison, Sandra P Melo, Samantha N Piekos, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2018
Enterotoxigenic <i>E. coli</i> virulence gene regulation in human infectionsAlexander A Crofts, Simone M Giovanetti, Erica J Rubin, et al.
Nature Medicine|April 5, 2016
Inflammatory signaling in human tuberculosis granulomas is spatially organizedMohlopheni J Marakalala, Ravikiran M Raju, Kirti Sharma, et al.
Diabetes Care|October 15, 2015
Insulin Dose and Cardiovascular Mortality in the ACCORD TrialElias S Siraj, Daniel J Rubin, Matthew C Riddle, et al.
Annals of the Rheumatic Diseases|January 1, 2017
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trialJohn Gerry Coghlan, Nazzareno Galiè, Joan Albert Barberà, et al.
Pageof 121